Clinical Practice Surveillance of the Use of Herceptin Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms HerSCin
- Sponsors Roche
- 01 Jan 2021 Results (n=870) published in the Anticancer Research
- 07 Mar 2019 Status changed from active, no longer recruiting to completed.
- 06 Dec 2018 Planned End Date changed from 30 Sep 2018 to 31 Jan 2019.